glp-1 parkinson's disease lancet Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Exenatide once a week versus

Semaglutide and Liraglutide: Clinical Trial Highlights Recent clinical trials exploring GLP-1 receptor agonists for NASH treatment have yielded promising results, establishing these agents as potential therapeutic options for this previously difficult-to-treat condition

J., Holst, J

Semaglutide use is increasingly associated with gastroparesis, a condition marked by delayed gastric emptying, causing nausea, vomiting, abdominal pain, bloating, satiety, acid reflux, and blood sugar fluctuations

TABLE 1 Primers used for RT-qPCR

JNK activation is associated with intracellular beta-amyloid accumulation

and Novo Nordisk alleging Mounjaro and Ozempic caused severe side effects, including vomiting and tooth loss